Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:

NCT ID: NCT04553887 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

AUTUMN
Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to evaluate the efficacy and the safety/ tolerability of Almonertinib in NSCLC patients with uncommon EGFR Mutation or EGFR exon 20 insertion mutations. Patients with EGFR exon 20 insertion mutations have to had at least one prior systemic treatment for locally advanced or metastatic NSCLC.

NCT ID: NCT04544644 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of Combination Therapy in NSCLC

Start date: September 2020
Phase: Phase 2
Study type: Interventional

This trial is a single arm, two cohorts, phase II study. All patients are stage IIIB-IV NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene. Cohort 1 includes patients with metastatic or recurrent NSCLC after progression on treatment with platinum-based chemotherapy and PD-1/PD-L1, given concurrently or sequentially. Cohort 2 includes treatment naïve patients with advanced NSCLC. All patients will recieve AK104 15mg/kg every 3 weeks(for up to 2 years) and anlotinib(12mg/d). The primary end point are objective response rate per RECIST1.1 and safety. Secondary end points are progression-free survival and overall survival.

NCT ID: NCT04530097 Not yet recruiting - NSCLC and Theropy Clinical Trials

Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Based on the recommendations of the guidelines, as well as the previous animal studies and clinical studies of our team, we designed and carried out prospective, randomized controlled, double-blind clinical studies to further expand the sample size to verify the efficacy of radiofrequency ablation combined with melatonin in the treatment of stage IA NSCLC. It is hoped that this combined treatment plan can delay the recurrence of lung cancer after RFA and prolong the survival time of patients.

NCT ID: NCT04506242 Not yet recruiting - NSCLC Clinical Trials

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

This trial will evaluate the safety and efficacy of Camrelizumab (SHR-1210) in combination with apatinib neoadjuvant therapy before surgery [neoadjuvant phase], followed by camrelizumab alone after surgery [adjuvant phase] in participants with resectable stage IIA-IIIA, and resectable IIIB (T3N2) non-small cell lung cancer (NSCLC).

NCT ID: NCT04500717 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

ACROSS2
Start date: October 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, controlled, phase III study.

NCT ID: NCT04500704 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

ACROSS1
Start date: October 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, controlled, phase III study.

NCT ID: NCT04492969 Not yet recruiting - NSCLC Stage IV Clinical Trials

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

By prospectively observing the time to the best therapeutic effect of non-small cell lung cancer after ICI treatment, the characteristics of lesion distribution when the best therapeutic effect is reached, and the phenotype of disease progression after ICI treatment response, the investigators intended to explore the failure pattern of NSCLC after the once effective ICI treatment. The investigators also aim to evaluate the feasibility and clinical value of radiotherapy for the treatment of oligo-progressive lesions after ICI.

NCT ID: NCT04473703 Not yet recruiting - Cardiac Event Clinical Trials

Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients

Start date: August 1, 2020
Phase:
Study type: Observational

This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included . All patients will follow up for at least 1 year. Patients with cardiac adverse reactions after PD-1/PD-L1 immune checkpoint inhibitor treatment at admission or during the subsequently follow-up period will randomly assigned a random number to each patient by computer random sequence. Patients with odd random number will treat with RASI(renin-angiotensin system inhibitors), and those with even random number will treat with ARNI(angiotensin-receptor-neprilysin inhibitor).

NCT ID: NCT04470076 Not yet recruiting - Surgery Clinical Trials

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Neoafa
Start date: July 10, 2020
Phase: Phase 2
Study type: Interventional

The recommended adjuvant therapy for stage Ⅱa-Ⅲb Non-small cell lung cancer (NSCLC) were perioperative chemotherapy. The adjuvant or neoadjuvant chemotherapy for early stage lung cancer improved about 5% 5-year survival. As for advanced NSCLC with epidermal growth factor receptor (EGFR) activating mutation, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) combination with chemotherapy had improved progression-free survival (PFS) compared with EGFR-TKI alone. We propose this trial of Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation, which would maximize benefit early in a patient's treatment course. At the same time, dynamic 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) was used to evaluate the standardized uptake value (SUV) and uptake rate constant (Ki) changes of lesions before and after treatment, so as to accurately and quantitatively monitor the tumor response of different therapy.

NCT ID: NCT04465968 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer Stage III

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

DEEP_OCEAN
Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

The safety and efficacy of multimodality treatment of pre- and post-operative durvalumab therapy after pre-operative chemoradiotherapy for resectable superior sulcus tumor (SST) and durvalumab maintenance therapy after chemoradiotherapy for unresectable SST